

### REMARKS

Applicants amend the Cross Reference to Related Applications to set forth the priority claim in the above-identified application.

Applicants amend claims 1-5 to delete reference to non-elected subject matter, without prejudice to applicants' ability to file and obtain patent protection for claims directed to this cancelled subject matter in applications claiming priority to the present application under 35 U.S.C. §120. Specifically, Applicants amend claims 1-5 to delete "phenyl" from the definition of Ring C.

Claim 9 is amended to specifically list the compounds, which applicant considers part of the present invention, into the claim.

Claim 10 is amended to correct an inadvertant typographical error.

Applicants amend claim 11 to recite the specific therapeutic agents in the claim. Support for this amendment is found in the specification at page 29, line 5 through page 30, line 6.


Claims 17-19 are amended to independent form.

Applicants amend claim 26 to independent form and also list the specific cancers associated with Aurora2 protein kinase. Support for this amendment is found in the specification at page 2, line 24 through page 3, line 2.

None of these amendments add any new matter.

Applicants respectfully request that the Examiner consider the foregoing remarks and enter the indicated amendments prior to substantive examination of this application.

Respectfully submitted,



Andrea L. C. Robidoux (Reg. No. 47,902)

Agent for Applicants

C/O Vertex Pharmaceuticals Inc.

130 Waverly St.

Cambridge, MA 02139-4242

Tel: (617)444-6731

Fax: (617)444-6483